News

Xarelto rivaroxaban Janssen Pharmaceuticals Deep Vein Thromosis Treament

Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), an oral anticoagulant, for the...

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible...

October 23, 2012 — A study found that a tailored therapy approach that adjusts the loading dose of clopidogrel according to measured platelet reactivity is superior to prasugrel therapy in...

October 2, 2012 — AstraZeneca has announced the results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results...

October 2, 2012 — A novel blood thinner recently approved by the U.S. Food and Drug Administration (FDA), Pradaxa (dabigatran), has been rapidly adopted into clinical practice, yet thus far has...

Pfizer Bristol-Myers Squibb Eliquis

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the new drug application (NDA) resubmission...

September 28, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-...

September 25, 2012 — Patients are often aggressively treated with anticoagulants, or blood thinners, to help prevent...

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

September 13, 2012 — Janssen Research & Development LLC announced that it has submitted the complete response to the U.S. Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban...

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with...

September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in...

August 30, 2012 — Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination...

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus aspirin. This standard is now being challenged by new agents —...

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially...

August 9, 2012 — The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT study, with the total number of patients randomized...

July 26, 2012 — Transgenomic Inc. has announced that National Government Services, the designated Medicare fiscal intermediary in Connecticut, has confirmed coverage for its proprietary...

July 20, 2012 — Ticagrelor, a blood-thinning drug approved by the U.S. Food and Drug Administration (FDA) in 2011, should be considered along with older blood thinners clopidogrel and prasugrel...

July 20, 2012 — The online clinical drug resource Drugs.com released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood thinners, proton-pump inhibitors, antipsychotics...